<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">FAS</journal-id>
<journal-id journal-id-type="hwp">spfas</journal-id>
<journal-title>Foot &amp; Ankle Specialist</journal-title>
<issn pub-type="ppub">1938-6400</issn>
<issn pub-type="epub">1938-7636</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1938640012463057</article-id>
<article-id pub-id-type="publisher-id">10.1177_1938640012463057</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Venous Thromboembolism and Foot and Ankle Surgery</article-title>
<subtitle>Current Updates 2012</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hentges</surname><given-names>Matthew J.</given-names></name>
<degrees>DPM</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Peterson</surname><given-names>Kyle S.</given-names></name>
<degrees>DPM</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Catanzariti</surname><given-names>Alan R.</given-names></name>
<degrees>DPM, FACFAS</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mendicino</surname><given-names>Robert W.</given-names></name>
<degrees>DPM, FACFAS</degrees>
</contrib>
</contrib-group>
<aff id="aff1-1938640012463057">Division of Foot and Ankle Surgery, The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania (MJH, KSP, ARC)</aff>
<aff id="aff2-1938640012463057">Pinnacle Orthopedics Associates, Salisbury, North Carolina (RWM)</aff>
<author-notes>
<corresp id="corresp1-1938640012463057">Robert W. Mendicino, DPM, FACFAS, Pinnacle Orthopedic Associates, 810 Mitchell Avenue, Salisbury, NC 28144; e-mail: <email>rmendicino@faiwp.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>5</volume>
<issue>6</issue>
<fpage>401</fpage>
<lpage>407</lpage>
<permissions>
<copyright-statement>© 2012 The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Abstract: Significant patient morbidity and mortality is associated with the development of venous thromboembolism (VTE) following orthopedic surgery. The majority of the literature supports proper prophylaxis following major orthopedic surgery involving hip and knee procedures. Foot and ankle surgery, however, is starkly contrasted because of the lack of recommendations. This article provides a comprehensive overview of the risk factors and incidence of VTE in foot and ankle surgery while also outlining the newest literature guidelines for prophylaxis.</p>
</abstract>
<kwd-group>
<kwd>deep vein thrombosis</kwd>
<kwd>vascular disease</kwd>
<kwd>other</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p><disp-quote>
<p>“Venous stasis and vascular injury may occur after foot and ankle trauma or surgery, especially when the lower extremity is immobilized.”</p>
</disp-quote></p>
<sec id="section1-1938640012463057" sec-type="intro">
<title>Introduction</title>
<p>Venous thromboembolic disease is a rare, yet potentially life-threatening complication of orthopedic surgery. Patients undergoing major orthopedic surgery are at high risk for venous thromboembolism (VTE). The published rate of deep venous thrombosis (DVT) after major orthopedic surgery (including knee or hip arthroplasty and hip fracture) is 45% to 80% without prophylaxis.<sup><xref ref-type="bibr" rid="bibr1-1938640012463057">1</xref></sup> The literature is less conclusive regarding the risk of VTE in patients undergoing surgical management of foot and ankle disorders, with published rates as high as 5.9%.<sup><xref ref-type="bibr" rid="bibr2-1938640012463057">2</xref></sup> Standardized guidelines for the use of VTE prophylaxis in foot and ankle surgery have not been developed. The 2008 consensus guidelines published by the American College of Chest Physicians (ACCP) concluded that routine use of prophylactic anticoagulants is not indicated in patients with isolated below-knee injuries, both osseous and tendinous in nature.<sup><xref ref-type="bibr" rid="bibr3-1938640012463057">3</xref></sup> The purpose of this article is to provide an overview of the pathophysiology, morbidity, and complications of VTE. This article also reviews the current literature for the incidence of VTE and the current recommendations for prophylaxis of VTE in foot and ankle surgery.</p>
</sec>
<sec id="section2-1938640012463057">
<title>Pathophysiology</title>
<p>Virchow described a triad of risk factors for VTE, including venous stasis, vascular endothelial abnormalities, and alterations in blood constituents, resulting in a hypercoagulable state.<sup><xref ref-type="bibr" rid="bibr4-1938640012463057">4</xref></sup> Venous stasis and vascular injury may occur after foot and ankle trauma or surgery, especially when the lower extremity is immobilized. Hypercoagulable states include both acquired and inherited conditions (<xref ref-type="table" rid="table1-1938640012463057">Table 1</xref>). Acquired risk factors include a prior history of VTE, surgery, trauma, airline travel, immobilization, age greater than 40, malignancy, congestive heart failure, recent myocardial infarction, paralysis, estrogen use, pregnancy or postpartum state, varicose veins, obesity, antiphospholipid syndrome, and hyperhomocysteinemia. Inherited conditions include the following: factor V Leiden, prothrombin G20210A, antithrombin deficiency, protein C deficiency, protein S deficiency, anticardiolipin antibody syndrome, and dysfibrinogenemia.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup></p>
<table-wrap id="table1-1938640012463057" position="float">
<label>Table 1.</label>
<caption><p>Risk Factors for the Development of VTE<sup><xref ref-type="table-fn" rid="table-fn2-1938640012463057">a</xref></sup></p></caption>
<graphic alternate-form-of="table1-1938640012463057" xlink:href="10.1177_1938640012463057-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Acquired Risk Factors</th>
<th align="center">Inherited Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior history of DVT or PE</td>
<td>Family history of DVT or PE</td>
</tr>
<tr>
<td>Surgery</td>
<td>Factor V Leiden mutation</td>
</tr>
<tr>
<td>Trauma</td>
<td>Prothrombin G20210A</td>
</tr>
<tr>
<td>Immobilization</td>
<td>Antithrombin III deficiency</td>
</tr>
<tr>
<td>Age &gt;40 years</td>
<td>Protein C deficiency</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>Protein S deficiency</td>
</tr>
<tr>
<td>Obesity</td>
<td>Anticardiolipin antibody syndrome</td>
</tr>
<tr>
<td>Malignancy</td>
<td>MTHFR gene variant <italic>C677T</italic></td>
</tr>
<tr>
<td>Oral contraceptive use</td>
<td><italic>PAI-1</italic> polymorphism gene</td>
</tr>
<tr>
<td>Pregnancy or postpartum state</td>
<td>Dysfibrinogenemia</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1938640012463057">
<p>Abbreviations: VTE, venous thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism; MTHFR, methylenetetrahydrofolate reductase.</p>
</fn>
<fn id="table-fn2-1938640012463057">
<label>a</label>
<p>Data are taken from other studies.<sup><xref ref-type="bibr" rid="bibr2-1938640012463057">2</xref>,<xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref>,<xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref>,<xref ref-type="bibr" rid="bibr7-1938640012463057">7</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Venous clots originate in the cusps of the valves in veins and may form in the superficial or deep venous system. These thrombi grow and extend to occlude the lumen of the vein and promote an inflammatory reaction. Postoperative DVT usually starts in the calf or at the site of venous trauma.<sup><xref ref-type="bibr" rid="bibr8-1938640012463057">8</xref></sup> Calf DVTs propagate into proximal thrombosis in 25% to 30% of cases.<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref>,<xref ref-type="bibr" rid="bibr8-1938640012463057">8</xref></sup> Approximately 40% of proximal DVTs embolize to the pulmonary vasculature, and 10% are reported as massive or fatal.<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref>,<xref ref-type="bibr" rid="bibr8-1938640012463057">8</xref></sup> It is important to remember that postoperative DVT of the lower limbs is often asymptomatic.<sup><xref ref-type="bibr" rid="bibr2-1938640012463057">2</xref>,<xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref>,<xref ref-type="bibr" rid="bibr8-1938640012463057">8</xref></sup> Pulmonary embolisms (PEs) can lead to pleural effusion, pulmonary infarct, or inability to oxygenate pulmonary venous return. If clots are occlusive of the pulmonary vasculature, the right heart can fail, leading to circulatory collapse and hypoxia, resulting in death.<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref></sup></p>
<p>Numerous risk factors are associated with the development of VTEs in foot and ankle patient (<xref ref-type="table" rid="table1-1938640012463057">Table 1</xref>). Caprini listed approximately 40 risk factors associated with the formation of VTEs and Slaybaugh et al<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref></sup> modified this to create a risk factor assessment guide for foot and ankle surgeons.<sup><xref ref-type="bibr" rid="bibr9-1938640012463057">9</xref></sup> The risk factors are itemized and totaled, and prophylaxis guidelines are based on the risk level. The more commonly cited factors include a history of DVT/PE, positive family history, obesity, smoking, immobilization, hereditary thrombophilias, history of malignancy, oral contraceptive use, and airline travel.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup></p>
</sec>
<sec id="section3-1938640012463057">
<title>Diagnosing Venous Thromboembolism</title>
<p>Clinical diagnosis of DVT is often difficult because many are asymptomatic as a result of incomplete occlusion of the vein or collateral circulation. Patients may present with calf pain, swelling, venous distention, discoloration, warmth, palpable cord, and positive Homan’s sign. Unilateral leg swelling increases clinical concern, and a calf size discrepancy of greater than 2 to 2.5 cm can be correlated with detection of thrombosis.<sup><xref ref-type="bibr" rid="bibr10-1938640012463057">10</xref></sup> Homan’s sign is often insensitive and nonspecific. It has been shown to be positive in 8% to 56% of patients with proven DVT. It has also been positive in 50% of patients found negative for DVT.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup> Therefore, patients with clinical signs and symptoms consistent with DVT should be further evaluated with imaging modalities.</p>
<p>Current imaging modalities used in the diagnosis of DVT include both noninvasive and invasive techniques. Ultrasonography is most commonly used because of its noninvasive nature, ease of use, cost, and high sensitivity and specificity. Kearon et al<sup><xref ref-type="bibr" rid="bibr11-1938640012463057">11</xref></sup> demonstrated an overall sensitivity and specificity for the diagnosis of proximal DVT of 89% to 100% and 94% to 100%, respectively.<sup><xref ref-type="bibr" rid="bibr11-1938640012463057">11</xref></sup> Sensitivity and specificity are reduced proximal to the distal iliac veins and distal to the popliteal level. Ultrasonography can also help distinguish acute from subacute or chronic clots based on sonographic features.<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref></sup> Duplex ultrasonography can also be used to monitor for proximal conversion of DVT.<sup><xref ref-type="bibr" rid="bibr12-1938640012463057">12</xref></sup> Although phlebography remains the gold standard, venous duplex ultrasonography is clearly the most commonly used modality to image a DVT.</p>
<p>Phlebography, or contrast venography, involves radiographic imaging of an extremity following the injection of a radiopaque dye. This procedure is limited because of its invasive nature and expense. Theoretically, it can induce thrombosis, and unlike ultrasonography, it cannot distinguish acute from chronic clots. This procedure is technically difficult because contrast medium is injected into a pedal vein, and serial radiographs are subsequently taken to evaluate for a filling defect. Venous access may be impractical or even impossible in a patient who has undergone a significant foot or ankle procedure.<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref></sup></p>
<p>Laboratory assay methods, such as D-dimer, determine the presence of breakdown products of cross-linked fibrin (D-dimers). Detection of these breakdown products can indicate the presence of active thrombosis. This assay is most useful as a tool to rule out DVT because of its lack of specificity. A negative D-dimer correlates with a very low incidence of thrombosis.</p>
</sec>
<sec id="section4-1938640012463057">
<title>Morbidity Following the Development of a DVT</title>
<p>Life-altering complications following the development of a DVT can occur. Proximal extension of the clot, pulmonary embolus, recurrence of a DVT, and postthrombotic syndrome are frequent manifestations following DVT.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup> The most common condition seen in the lower extremity following DVT is postthrombotic syndrome, often presenting with symptoms such as pain, cramps, heaviness, parasthesia, and pruritis.<sup><xref ref-type="bibr" rid="bibr13-1938640012463057">13</xref></sup> Severe postthrombotic syndrome can manifest as a chronic lower-extremity ulceration, ultimately leading to a poorer quality of life.<sup><xref ref-type="bibr" rid="bibr13-1938640012463057">13</xref></sup></p>
<p>Pulmonary embolus (PE) represents the most serious complication following the development of a DVT. A PE occurs when a thrombus migrates proximally from the lower extremity into the pulmonary system. Greater than 90% of patients’ deaths caused by a PE occur in untreated patients without the diagnosis made in life.<sup><xref ref-type="bibr" rid="bibr14-1938640012463057">14</xref></sup> Symptoms such as dyspnea, cough, hemoptysis, pleuritic pain, and tachypnea should be recognized and treated immediately. According to the RIETE (Registro Informatizado de la Enfermedad Tromboembolica venosa) registry, the cumulative rates for overall mortality and fatal PE were 8.65% and 1.68%, respectively.<sup><xref ref-type="bibr" rid="bibr15-1938640012463057">15</xref></sup></p>
<p>Recurrence of a future DVT following the initial diagnosis of an acute event is a serious concern. Patients are 40 times more likely to suffer a recurrence of a DVT compared with unaffected individuals.<sup><xref ref-type="bibr" rid="bibr16-1938640012463057">16</xref></sup> In addition, patients are at a higher risk for the development of postthrombotic syndrome or chronic thromboembolic pulmonary hypertension with a recurrent DVT or PE.</p>
</sec>
<sec id="section5-1938640012463057">
<title>Review of the Incidence of VTE in Foot and Ankle Surgery</title>
<p>The incidence of symptomatic VTE events following surgery of the foot and ankle has been well documented to be relatively low; however, the true incidence is likely underreported because of clinically asymptomatic events (<xref ref-type="table" rid="table2-1938640012463057">Table 2</xref>).<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref>,<xref ref-type="bibr" rid="bibr17-1938640012463057">17</xref><xref ref-type="bibr" rid="bibr18-1938640012463057"/><xref ref-type="bibr" rid="bibr19-1938640012463057"/><xref ref-type="bibr" rid="bibr20-1938640012463057"/><xref ref-type="bibr" rid="bibr21-1938640012463057"/><xref ref-type="bibr" rid="bibr22-1938640012463057"/><xref ref-type="bibr" rid="bibr23-1938640012463057"/><xref ref-type="bibr" rid="bibr24-1938640012463057"/><xref ref-type="bibr" rid="bibr25-1938640012463057"/>-<xref ref-type="bibr" rid="bibr26-1938640012463057">26</xref></sup> One of the largest and earliest multicenter studies on foot and ankle surgery VTE events reported an incidence of 0.22% and 0.15% for DVT and PE, respectively, in more than 2700 patients.<sup><xref ref-type="bibr" rid="bibr17-1938640012463057">17</xref></sup> However, this study only detected symptomatic VTE events, and there was no standard for thromboprophylaxis.<sup><xref ref-type="bibr" rid="bibr17-1938640012463057">17</xref></sup></p>
<table-wrap id="table2-1938640012463057" position="float">
<label>Table 2.</label>
<caption><p>Summary of the Incidence of VTE Following Foot and Ankle Surgery</p></caption>
<graphic alternate-form-of="table2-1938640012463057" xlink:href="10.1177_1938640012463057-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="center">Design</th>
<th align="center">Number of Patients</th>
<th align="center">Patients Screened</th>
<th align="center">Incidence of DVT</th>
<th align="center">Incidence of PE</th>
<th align="center">Time to Diagnosis of VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mizel et al (1998)<sup><xref ref-type="bibr" rid="bibr17-1938640012463057">17</xref></sup></td>
<td>Prospective</td>
<td>2733</td>
<td>Symptomatic only</td>
<td>0.22% (6 of 2733)</td>
<td>0.15% (4 of 2733)</td>
<td>34.8 days</td>
</tr>
<tr>
<td>Solis and Saxby (2002)<sup><xref ref-type="bibr" rid="bibr18-1938640012463057">18</xref></sup></td>
<td>Prospective</td>
<td>201</td>
<td>All</td>
<td>3.5% (7 of 201)</td>
<td>0% (0 of 201)</td>
<td>10.55 days</td>
</tr>
<tr>
<td>Slaybaugh et al (2003)<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref></sup></td>
<td>Retrospective</td>
<td>1821</td>
<td>Symptomatic only</td>
<td>0.5% (9 of 1821)</td>
<td>0.16% (3 of 1821)</td>
<td>31.5 days</td>
</tr>
<tr>
<td>Radl et al (2003)<sup><xref ref-type="bibr" rid="bibr22-1938640012463057">22</xref></sup></td>
<td>Prospective</td>
<td>100</td>
<td>All</td>
<td>4% (4 of 100)</td>
<td>0% (0 of 100)</td>
<td>29 days</td>
</tr>
<tr>
<td>Hanslow et al (2006)<sup><xref ref-type="bibr" rid="bibr19-1938640012463057">19</xref></sup></td>
<td>Retrospective</td>
<td>602</td>
<td>Symptomatic only</td>
<td>4% (24 of 602)</td>
<td>1.3% (8 of 602)</td>
<td>NR</td>
</tr>
<tr>
<td>Lapidus et al (2007)<sup><xref ref-type="bibr" rid="bibr27-1938640012463057">27</xref></sup></td>
<td>Prospective</td>
<td>226</td>
<td>All</td>
<td>25.7% (58 of 226)</td>
<td>0% (0 of 226)</td>
<td>44 days</td>
</tr>
<tr>
<td>Lapidus et al (2007)<sup><xref ref-type="bibr" rid="bibr28-1938640012463057">28</xref></sup></td>
<td>Prospective</td>
<td>96</td>
<td>All</td>
<td>38.5% (37 of 96)</td>
<td>0% (0 of 96)</td>
<td>28 days</td>
</tr>
<tr>
<td>Wukich and Waters (2008)<sup><xref ref-type="bibr" rid="bibr20-1938640012463057">20</xref></sup></td>
<td>Retrospective</td>
<td>1000</td>
<td>Symptomatic only</td>
<td>0.4% (4 of 1000)</td>
<td>0.3% (3 of 1000)</td>
<td>35.7 days</td>
</tr>
<tr>
<td>Felcher et al (2009)<sup><xref ref-type="bibr" rid="bibr21-1938640012463057">21</xref></sup></td>
<td>Retrospective</td>
<td>7264</td>
<td>Symptomatic only</td>
<td>0.17% (12 of 7264)</td>
<td>0.14% (10 of 7264)</td>
<td>52 days</td>
</tr>
<tr>
<td>SooHoo et al (2010)<sup><xref ref-type="bibr" rid="bibr24-1938640012463057">24</xref></sup></td>
<td>Retrospective</td>
<td>1477</td>
<td>Symptomatic only</td>
<td>NR</td>
<td>0.27% (4 of 1477)</td>
<td>Within 90 days</td>
</tr>
<tr>
<td>Jameson et al (2011)<sup><xref ref-type="bibr" rid="bibr26-1938640012463057">26</xref></sup></td>
<td>Retrospective</td>
<td>87 241</td>
<td>Symptomatic only</td>
<td>0.07% (58 of 87 241)</td>
<td>0.11% (93 of 87 241)</td>
<td>NR</td>
</tr>
<tr>
<td>Pelet et al (2012)<sup><xref ref-type="bibr" rid="bibr29-1938640012463057">29</xref></sup></td>
<td>Retrospective</td>
<td>1540</td>
<td>Symptomatic</td>
<td>2.66% (41 of 1540)</td>
<td>0.32% (5 of 1540)</td>
<td>NR</td>
</tr>
<tr>
<td>Patel et al (2012)<sup><xref ref-type="bibr" rid="bibr23-1938640012463057">23</xref></sup></td>
<td>Retrospective</td>
<td>1172</td>
<td>Symptomatic</td>
<td>0.43% (5 of 1172)</td>
<td>0.34% (4 of 1172)</td>
<td>Within 90 days</td>
</tr>
<tr>
<td>Shibuya et al (2012)<sup><xref ref-type="bibr" rid="bibr25-1938640012463057">25</xref></sup></td>
<td>Retrospective</td>
<td>75 664</td>
<td>Symptomatic</td>
<td>0.28% (169 of 60 529)</td>
<td>0.21% (130 of 60 529)</td>
<td>NR</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1938640012463057">
<p>Abbreviations: VTE, venous thromboembolism; DVT, deep venous thrombosis; PE, pulmonary embolism; NR, not reported.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>A prospective study, performed in 2002, did report a true DVT incidence of 3.5% in 201 patients, all of whom underwent postoperative ultrasound without receiving any perioperative prophylaxis.<sup><xref ref-type="bibr" rid="bibr18-1938640012463057">18</xref></sup> They concluded that prophylaxis following foot and ankle surgery is not required because of the low rate and progression of DVT in the postoperative period. A retrospective review of 8 podiatric surgeons affiliated with the Grant Podiatric Surgical Residency Program revealed an incidence of DVT in 9/1821 (0.5%) surgical patients.<sup><xref ref-type="bibr" rid="bibr6-1938640012463057">6</xref></sup> Three of these patients with documented DVT progressed to a nonfatal PE.</p>
<p>Hanslow et al<sup><xref ref-type="bibr" rid="bibr19-1938640012463057">19</xref></sup> reported one of the highest incidences of DVT in 4% of 602 patients following foot and ankle surgery in a retrospective review. They also found no association between VTE disease and medication used, type of foot or ankle procedure, type of anesthesia, or the use of a tourniquet.</p>
<p>Two recent studies found similar incidences of symptomatic VTE events.<sup><xref ref-type="bibr" rid="bibr20-1938640012463057">20</xref>,<xref ref-type="bibr" rid="bibr21-1938640012463057">21</xref></sup> Wukich and Waters<sup><xref ref-type="bibr" rid="bibr20-1938640012463057">20</xref></sup> reported an incidence of symptomatic DVT in the lower extremity of 0.4% and an incidence of 0.3% for PE in 1000 patients. Felcher et al,<sup><xref ref-type="bibr" rid="bibr21-1938640012463057">21</xref></sup> likewise, identified an overall postprocedure incidence of VTE in 0.3% of 7264 patients.<sup><xref ref-type="bibr" rid="bibr21-1938640012463057">21</xref></sup></p>
<p>Finally, several studies have reported the incidence of VTE events correlated with a surgical procedure in the foot or ankle.<sup><xref ref-type="bibr" rid="bibr22-1938640012463057">22</xref><xref ref-type="bibr" rid="bibr23-1938640012463057"/><xref ref-type="bibr" rid="bibr24-1938640012463057"/><xref ref-type="bibr" rid="bibr25-1938640012463057"/>-<xref ref-type="bibr" rid="bibr26-1938640012463057">26</xref></sup> Radl and colleagues,<sup><xref ref-type="bibr" rid="bibr22-1938640012463057">22</xref></sup> in 2003, reported a DVT rate of 4% following 100 consecutive bunion surgeries. More recently, a DVT rate of 0.43% and PE rate of 0.34% was found in 1172 patients with complete ruptures of the Achilles tendon.<sup><xref ref-type="bibr" rid="bibr23-1938640012463057">23</xref></sup></p>
<p>Foot and ankle trauma has also been reported as a significant risk factor for the development of a VTE. In 2010, SooHoo et al,<sup><xref ref-type="bibr" rid="bibr24-1938640012463057">24</xref></sup> reported a readmission rate for PE of 0.27% of 1477 patients following open reduction and internal fixation of metatarsal fractures. Similarly, Shibuya et al,<sup><xref ref-type="bibr" rid="bibr25-1938640012463057">25</xref></sup> in 2012, reported the incidence of DVT and PE to be 0.28% and 0.21%, respectively, in the National Trauma Data Bank set.</p>
<p>Statistics for postoperative foot and ankle surgical patients has been reported in the English National Health Service.<sup><xref ref-type="bibr" rid="bibr26-1938640012463057">26</xref></sup> They reported DVT, PE, and mortality rates of 0.12%, 0.17%, and 0.37%, respectively, for ankle fracture surgery. For first metatarsal osteotomy surgery, DVT, PE, and mortality rates were 0.01%, 0.02%, and 0.04%, respectively, and for hindfoot fusion surgery, the rates were 0.03%, 0.11%, and 0.11%, respectively. Finally, the rate of PE in total ankle replacement surgery was 0.06%, and there were no recorded DVTs or deaths.<sup><xref ref-type="bibr" rid="bibr26-1938640012463057">26</xref></sup></p>
</sec>
<sec id="section6-1938640012463057">
<title>Who and How Should We Use DVT Prophylaxis in Foot and Ankle Surgery?</title>
<p>As mentioned previously, numerous acquired and inherited risk factors exist for the development of postoperative VTE following foot and ankle surgery. Evidence-based risk factors for VTE include a prior history of DVT or PE, advanced age, obesity, smoking, history of malignancy, immobilization, a positive family history, and inherited thrombophilias.<sup><xref ref-type="bibr" rid="bibr2-1938640012463057">2</xref>,<xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup> In 2011, we presented a case report of a middle-aged woman with an inherited thrombophilia who developed a DVT following bunion surgery.<sup><xref ref-type="bibr" rid="bibr7-1938640012463057">7</xref></sup> Following an investigative hypercoagulable blood panel, she was positive for 2 rare genetic mutations: homozygous positive state for methylenetetrahydrofolate reductase gene variant <italic>C677T</italic> and homozygous 4G deletion allege for plasminogen activator-1 (<italic>PAI-1</italic>) polymorphism gene. Although rare, we believe that this was a contributing factor to the development of her DVT. Surgeons should be vigilant of all potential risk factors that place the patient at a higher risk of the development of a VTE event. A thorough history and physical should be performed, and prophylaxis should be instituted accordingly. Frequently, many hospital systems implement a VTE risk factor assessment algorithm to assist in prophylaxis (<xref ref-type="fig" rid="fig1-1938640012463057">Figure 1</xref>).</p>
<fig id="fig1-1938640012463057" position="float">
<label>Figure 1.</label>
<caption><p>The Western Pennsylvnia Hospital’s VTE Risk Assessment Form.</p>
<p>Abbreviation: VTE, venous thromboembolism.</p></caption>
<graphic xlink:href="10.1177_1938640012463057-fig1.tif"/>
</fig>
</sec>
<sec id="section7-1938640012463057">
<title>Thromboprophylaxis in Foot and Ankle Surgery</title>
<p>There are no current published guidelines regarding the use of thromboprophylaxis for foot and ankle surgical patients. The ACCP recently published the ninth edition of the current guidelines for antithrombotic therapy and prevention of thrombosis in orthopedic patients.<sup><xref ref-type="bibr" rid="bibr30-1938640012463057">30</xref></sup> The main indications for prophylaxis in orthopedic surgery included total hip arthroplasty (THA), total knee arthroplasty (TKA), and hip fracture surgery (HFS). The indications for the use of thromboprophylaxis in foot and ankle surgery have not been outlined because of the low incidence of postoperative DVTs. However, there are numerous recommendations for prophylaxis of VTEs.</p>
<p>Prophylaxis of VTE includes both medical and mechanical modalities. The medical prophylactic modalities include warfarin, heparin, low-molecular-weight heparin (LMWH), fondaparinux, and aspirin. During the postoperative period, the more commonly prescribed prophylactic agents include LMWH and fondaparinux. Mechanical prophylaxis against DVT attempts to recreate the natural mechanisms of the body without the unwanted hemorrhagic side effects of LMWH, warfarin, and aspirin. These modalities include intermittent compression pumps and graduated elastic compression stockings.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup></p>
<p>LMWH are commonly used for outpatient prevention of DVTs. The advantages include ease of dosing, no required lab monitoring, and self-administration kits. Enoxaparin is commonly prescribed following foot and ankle surgery at 40 mg injected subcutaneously daily for 10 to 14 days.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup> There is also a renal dose of 30 mg available (creatinine clearance &lt; 30 mL/min). LMWH is effective through inhibition of thrombin (factor IIa) and factor Xa. LMWH also enhances the activity of antithrombin and promotes tissue factor pathway inhibition. When compared with unfractionated heparin, LMWH has a higher bioavailability and more consistent pharmacokinetics. This allows for subcutaneous dosing at fixed intervals.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref></sup> LMWH has been given grade IB recommendations for patients undergoing TKA or THA as well as HFS.<sup><xref ref-type="bibr" rid="bibr30-1938640012463057">30</xref></sup> We were unable to find any studies relating the use of enoxaparin in postoperative prevention of VTE in foot and ankle surgery.</p>
<p>Fondaparinux is a synthetic, selective factor Xa inhibitor. Similar to enoxaparin, fondaparinux does not require laboratory monitoring and is administered once daily (2.5 mg) subcutaneously. Fondaparinux is contraindicated in patients with severe renal impairment (creatinine clearance &lt; 30 mL/min). It has been shown to be more efficacious than enoxaparin in the prevention of VTE following TKA (6.8% and 13.7%, respectively).<sup><xref ref-type="bibr" rid="bibr31-1938640012463057">31</xref></sup> Fondaparinux has been given grade IB recommendations for patients undergoing TKA or THA as well as HFS.<sup><xref ref-type="bibr" rid="bibr30-1938640012463057">30</xref></sup> Our review of the literature found no current studies related to the use of fondaparinux and foot and ankle surgery.</p>
<p>Rivaroxaban is an oral factor Xa inhibitor indicated for the prevention of VTE in patients undergoing TKA or THA. It is contraindicated in patients with severe renal impairment (creatinine clearance &lt;30 mL/min). Rivaroxaban has been given grade IB recommendations by the ACCP guidelines for prevention of VTE following THA and TKA.<sup><xref ref-type="bibr" rid="bibr30-1938640012463057">30</xref></sup></p>
<p>Aspirin has also been recommended for medical prophylaxis against VTE. Aspirin decreases platelet aggregation by irreversibly inhibiting the cyclooxygenase pathway through prostaglandin H.<sup><xref ref-type="bibr" rid="bibr32-1938640012463057">32</xref></sup> The Pulmonary Embolism Prevention (PEP) trial, in 2000, found that aspirin produced proportional reductions in PE and symptomatic DVT by 43% and 29%, respectively, in hip fracture patients.<sup><xref ref-type="bibr" rid="bibr33-1938640012463057">33</xref></sup> Furthermore, aspirin also prevented 4 fatal PEs per 1000 patients, correlating to a proportional reduction of 58%.<sup><xref ref-type="bibr" rid="bibr33-1938640012463057">33</xref></sup> Previous ACCP guidelines have recommended against the use of aspirin as the sole method for thromboprophylaxis.<sup><xref ref-type="bibr" rid="bibr3-1938640012463057">3</xref></sup> However, the ninth edition ACCP guidelines now recommend that aspirin may be used alone for a minimum of 10-14 days for thromboprophylaxis in patients undergoing TKA and THA and in hip fracture patients.<sup><xref ref-type="bibr" rid="bibr30-1938640012463057">30</xref></sup> However, no standardized guidelines for foot and ankle surgical patients have been outlined.</p>
</sec>
<sec id="section8-1938640012463057">
<title>Complications of DVT Prophylaxis</title>
<p>Although it is important to determine the nature and course of medical DVT prophylaxis in patients undergoing surgery, bleeding risks do exist. A systematic review in 2006 reported on both minor and major bleeding complications after medical antithrombotic prophylaxis.<sup><xref ref-type="bibr" rid="bibr34-1938640012463057">34</xref></sup> Minor bleeding complications included the following: injection site bleeding, 6.9%; wound hematoma, 5.7%; drain site bleeding, 2%; and hematuria, 1.6%. Major bleeding complications included 0.2% gastrointestinal bleeding and 0.08% retroperitoneal bleeding. They also reported a 2% rate of discontinuation of medical prophylaxis.<sup><xref ref-type="bibr" rid="bibr34-1938640012463057">34</xref></sup></p>
<p>Three studies published rates from 1.5% to 5.1% for postoperative major wound or systemic hemorrhagic complications following orthopedic procedures in patients who received medical prophylaxis.<sup><xref ref-type="bibr" rid="bibr35-1938640012463057">35</xref><xref ref-type="bibr" rid="bibr36-1938640012463057"/>-<xref ref-type="bibr" rid="bibr37-1938640012463057">37</xref></sup> On the other hand, 2 recent prospective, randomized, placebo-controlled, double-blinded studies of medical VTE prophylaxis using dalteparin in foot and ankle surgical patients reported no major bleeding complications in more than 370 patients.<sup><xref ref-type="bibr" rid="bibr27-1938640012463057">27</xref>,<xref ref-type="bibr" rid="bibr28-1938640012463057">28</xref></sup></p>
<p>A second concern following medical therapy for DVT prophylaxis is the potentially life-threatening development of heparin-induced thrombocytopenia (HIT). HIT is a complication of receiving heparin or any heparin-derived product. It most commonly develops as a systemic autoimmune response by the formation of complexes between heparin and endogenous platelet factor 4.<sup><xref ref-type="bibr" rid="bibr37-1938640012463057">37</xref></sup> Manifestations often occur, classically, between 5 and 10 days of exposure to a heparin product, and it is characterized by a decrease in greater than 50% of baseline platelets.<sup><xref ref-type="bibr" rid="bibr38-1938640012463057">38</xref></sup> Serious or life-threatening complications can arise such as a paradoxical thrombotic disease, extremity ischemia, limb amputation, or death.<sup><xref ref-type="bibr" rid="bibr5-1938640012463057">5</xref>,<xref ref-type="bibr" rid="bibr38-1938640012463057">38</xref></sup> Once diagnosed, the immediate treatment involves cessation of all heparin products and the implementation of an anticoagulation therapy that can both treat active thrombosis and also prevent further thrombosis while the platelet level increases.<sup><xref ref-type="bibr" rid="bibr38-1938640012463057">38</xref></sup> Current therapy includes direct thrombin inhibitors, such as lepirudin and argatroban.<sup><xref ref-type="bibr" rid="bibr38-1938640012463057">38</xref></sup> One study in 2006, reported an incidence of HIT in 6.5% of patients treated with unfractionated heparin after orthopedic surgery, compared with an incidence of only 1% or less following other types of surgery.<sup><xref ref-type="bibr" rid="bibr39-1938640012463057">39</xref></sup></p>
</sec>
<sec id="section9-1938640012463057" sec-type="conclusions">
<title>Conclusion</title>
<p>VTE prophylaxis following foot and ankle surgery remains a highly debated topic. As demonstrated in the literature reviewed, the majority of support for VTE prophylaxis correlates with major orthopedic surgery. Recommendations for prophylaxis in foot and ankle surgery have not been formally outlined, given the relatively low incidence of VTE events in surgical patients. However, even with a documented low incidence of postoperative VTE, an occurrence of a DVT or PE can lead to significant patient morbidity or even mortality. It is essential to obtain a thorough history and physical for proper identification of a patient at risk. Once identified, careful risk assessment must be studied and proper prophylaxis should be implemented after a thorough discussion with the patient. The authors commonly use 40 mg of enoxaparin daily for 14 days in patients undergoing hindfoot or ankle procedures who exhibit greater than 3 significant risk factors. We follow our postoperative patients closely for the first month to recognize thromboprophylaxis complications if they arise. With heightened awareness and research regarding VTE, physicians can safely attempt to prevent significant morbidity and mortality following foot and ankle surgery.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1938640012463057">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muntz</surname><given-names>J</given-names></name>
</person-group>. <article-title>Thromboprophylaxis in orthopedic surgery: how long is long enough?</article-title> <source>Am J Orthop</source>. <year>2009</year>;<volume>38</volume>:<fpage>394</fpage>-<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr2-1938640012463057">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schade</surname><given-names>VL</given-names></name>
<name><surname>Roukis</surname><given-names>TS</given-names></name>
</person-group>. <article-title>Antithrombotic pharmacologic prophylaxis use during conservative and surgical management of foot and ankle disorders: a systematic review</article-title>. <source>Clin Podiatr Med Surg</source>. <year>2011</year>;<volume>28</volume>:<fpage>571</fpage>-<lpage>588</lpage>.</citation>
</ref>
<ref id="bibr3-1938640012463057">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Geerts</surname><given-names>WH</given-names></name>
<name><surname>Bergqvist</surname><given-names>D</given-names></name>
<name><surname>Pineo</surname><given-names>GF</given-names></name><etal/>
</person-group>. <article-title>Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title> (<edition>8th edition</edition>). <source>Chest</source>. <year>2008</year>;<volume>133</volume>:<fpage>381S</fpage>-<lpage>453S</lpage>.</citation>
</ref>
<ref id="bibr4-1938640012463057">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Virchow</surname><given-names>R</given-names></name>
</person-group>. <article-title>Neuer fall von todlicher. Embolie der lungenarterien</article-title>. <source>Arch Pathol Anat</source>. <year>1856</year>;<volume>10</volume>:<fpage>225</fpage>.</citation>
</ref>
<ref id="bibr5-1938640012463057">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayle</surname><given-names>RE</given-names><suffix>Jr</suffix></name>
<name><surname>DiGiovanni</surname><given-names>CW</given-names></name>
<name><surname>Lin</surname><given-names>SS</given-names></name><etal/>
</person-group>. <article-title>Current concepts review: venous thromboembolic disease in foot and ankle surgery</article-title>. <source>Foot Ankle Int</source>. <year>2007</year>;<volume>28</volume>:<fpage>1207</fpage>-<lpage>1216</lpage>.</citation>
</ref>
<ref id="bibr6-1938640012463057">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Slaybaugh</surname><given-names>RS</given-names></name>
<name><surname>Beasley</surname><given-names>BD</given-names></name>
<name><surname>Massa</surname><given-names>EG</given-names></name>
</person-group>. <article-title>Deep venous thrombosis risk assessment, incidence, and prophylaxis in foot and ankle surgery</article-title>. <source>Clin Podiatr Med Surg</source>. <year>2003</year>;<volume>20</volume>:<fpage>269</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr7-1938640012463057">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peterson</surname><given-names>KS</given-names></name>
<name><surname>Mendicino</surname><given-names>RW</given-names></name>
<name><surname>Catanzariti</surname><given-names>AR</given-names></name>
<name><surname>Saltrick</surname><given-names>KS</given-names></name>
</person-group>. <article-title>Deep vein thrombosis after bunionectomy: a case report of two genetic mutations</article-title>. <source>J Foot Ankle Surg</source>. <year>2011</year>;<volume>50</volume>:<fpage>733</fpage>-<lpage>735</lpage>.</citation>
</ref>
<ref id="bibr8-1938640012463057">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hardy</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Thromboembolic prophylaxis in foot and ankle surgery: what should we do?</article-title> <source>Foot Ankle Spec</source>. <year>2011</year>;<volume>4</volume>:<fpage>120</fpage>-<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr9-1938640012463057">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caprini</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Thrombosis risk assessment as a guide to quality patient care</article-title>. <source>Dis Mon</source>. <year>2005</year>;<volume>51</volume>:<fpage>70</fpage>-<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr10-1938640012463057">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>D</given-names></name>
<name><surname>Setnik</surname><given-names>G</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
</person-group>. <article-title>Physical examination findings in deep venous thrombosis</article-title>. <source>Emerg Med Clin North Am</source>. <year>2001</year>;<volume>19</volume>:<fpage>869</fpage>-<lpage>876</lpage>.</citation>
</ref>
<ref id="bibr11-1938640012463057">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kearon</surname><given-names>C</given-names></name>
<name><surname>Julian</surname><given-names>JA</given-names></name>
<name><surname>Math</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Noninvasive diagnosis of deep venous thrombosis</article-title>. <source>Ann Intern Med</source>. <year>1998</year>;<volume>128</volume>:<fpage>663</fpage>-<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr12-1938640012463057">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deitcher</surname><given-names>SR</given-names></name>
<name><surname>Caprini</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Calf deep venous thrombosis should be treated with anticoagulation</article-title>. <source>Med Clin North Am</source>. <year>2003</year>;<volume>87</volume>:<fpage>1157</fpage>-<lpage>1164</lpage>.</citation>
</ref>
<ref id="bibr13-1938640012463057">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kahn</surname><given-names>S</given-names></name>
<name><surname>Partsch</surname><given-names>H</given-names></name>
<name><surname>Vedantham</surname><given-names>S</given-names></name><etal/>
</person-group>; <collab>on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis</collab>. <article-title>Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization</article-title>. <source>J Thromb Haemost</source>. <year>2009</year>;<volume>7</volume>:<fpage>879</fpage>-<lpage>883</lpage>.</citation>
</ref>
<ref id="bibr14-1938640012463057">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baglin</surname><given-names>T</given-names></name>
</person-group>. <article-title>What happens after venous thromboembolism</article-title>. <source>J Thromb Haemost</source>. <year>2009</year>;<volume>7</volume>(<supplement>suppl 1</supplement>):<fpage>287</fpage>-<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr15-1938640012463057">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laporte</surname><given-names>S</given-names></name>
<name><surname>Mismetti</surname><given-names>P</given-names></name>
<name><surname>Decousus</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Clinical predictors for fatal pulmonary embolism in 15 520 patients venous thromboembolism: findings from the Registro Informatizado de la Enfermedad Tromboembolica venosa (RIETE) Registry</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>117</volume>:<fpage>1711</fpage>-<lpage>1716</lpage>.</citation>
</ref>
<ref id="bibr16-1938640012463057">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kearon</surname><given-names>C</given-names></name>
</person-group>. <article-title>Natural history of venous thromboembolism</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>122</fpage>-<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr17-1938640012463057">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mizel</surname><given-names>MS</given-names></name>
<name><surname>Temple</surname><given-names>HT</given-names></name>
<name><surname>Michelson</surname><given-names>JD</given-names></name><etal/>
</person-group>. <article-title>Thromboembolism after foot and ankle surgery: a multicenter study</article-title>. <source>Clin Orthop Relat Res</source>. <year>1998</year>;<volume>348</volume>:<fpage>180</fpage>-<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr18-1938640012463057">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solis</surname><given-names>G</given-names></name>
<name><surname>Saxby</surname><given-names>T</given-names></name>
</person-group>. <article-title>Incidence of DVT following surgery of the foot and ankle</article-title>. <source>Foot Ankle Int</source>. <year>2002</year>;<volume>23</volume>:<fpage>411</fpage>-<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr19-1938640012463057">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hanslow</surname><given-names>SS</given-names></name>
<name><surname>Grujic</surname><given-names>L</given-names></name>
<name><surname>Slater</surname><given-names>HK</given-names></name>
<name><surname>Chen</surname><given-names>D</given-names></name>
</person-group>. <article-title>Thromboembolic disease after foot and ankle surgery</article-title>. <source>Foot Ankle Int</source>. <year>2006</year>;<volume>27</volume>:<fpage>693</fpage>-<lpage>695</lpage>.</citation>
</ref>
<ref id="bibr20-1938640012463057">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wukich</surname><given-names>DK</given-names></name>
<name><surname>Waters</surname><given-names>DH</given-names></name>
</person-group>. <article-title>Thromboembolism following foot and ankle surgery: a case series and literature review</article-title>. <source>J Foot Ankle Surg</source>. <year>2008</year>;<volume>47</volume>:<fpage>243</fpage>-<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr21-1938640012463057">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Felcher</surname><given-names>AH</given-names></name>
<name><surname>Mularski</surname><given-names>RA</given-names></name>
<name><surname>Mosen</surname><given-names>DM</given-names></name><etal/>
</person-group>. <article-title>Incidence and risk factors for venous thromboembolic disease in podiatric surgery</article-title>. <source>Chest</source>. <year>2009</year>;<volume>135</volume>:<fpage>917</fpage>-<lpage>922</lpage>.</citation>
</ref>
<ref id="bibr22-1938640012463057">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Radl</surname><given-names>R</given-names></name>
<name><surname>Kastner</surname><given-names>N</given-names></name>
<name><surname>Aigner</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Venous thrombosis after hallux valgus surgery</article-title>. <source>J Bone Joint Surg</source>. <year>2003</year>;<volume>85-A</volume>:<fpage>1204</fpage>-<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr23-1938640012463057">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>A</given-names></name>
<name><surname>Ogawa</surname><given-names>B</given-names></name>
<name><surname>Charlton</surname><given-names>T</given-names></name>
<name><surname>Thordarson</surname><given-names>D</given-names></name>
</person-group>. <article-title>Incidence of deep vein thrombosis and pulmonary embolism after Achilles tendon rupture</article-title>. <source>Clin Orthop Rel Res</source>. <year>2012</year>;<volume>470</volume>:<fpage>270</fpage>-<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr24-1938640012463057">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>SooHoo</surname><given-names>NF</given-names></name>
<name><surname>Farng</surname><given-names>E</given-names></name>
<name><surname>Zingmond</surname><given-names>DS</given-names></name>
</person-group>. <article-title>Incidence of pulmonary embolism following surgical treatment of metatarsal fractures</article-title>. <source>Foot Ankle Int</source>. <year>2010</year>;<volume>31</volume>:<fpage>600</fpage>-<lpage>603</lpage>.</citation>
</ref>
<ref id="bibr25-1938640012463057">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shibuya</surname><given-names>N</given-names></name>
<name><surname>Frost</surname><given-names>CH</given-names></name>
<name><surname>Campbell</surname><given-names>JD</given-names></name><etal/>
</person-group>. <article-title>Incidence of acute deep vein thrombosis and pulmonary embolism in foot and ankle trauma: analysis of the National Trauma Data Bank</article-title>. <source>J Foot Ankle Surg</source>. <year>2012</year>;<volume>51</volume>:<fpage>63</fpage>-<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr26-1938640012463057">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jameson</surname><given-names>SS</given-names></name>
<name><surname>Augustine</surname><given-names>A</given-names></name>
<name><surname>James</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Venous thromboembolic events following foot and ankle surgery in the English National Health Service</article-title>. <source>J Bone Joint Surg</source>. <year>2011</year>;<volume>93-B</volume>:<fpage>490</fpage>-<lpage>497</lpage>.</citation>
</ref>
<ref id="bibr27-1938640012463057">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lapidus</surname><given-names>LJ</given-names></name>
<name><surname>Ponzer</surname><given-names>S</given-names></name>
<name><surname>Elvin</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study</article-title>. <source>Acta Orthop</source>. <year>2007</year>;<volume>78</volume>:<fpage>528</fpage>-<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr28-1938640012463057">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lapidus</surname><given-names>LJ</given-names></name>
<name><surname>Rosfers</surname><given-names>S</given-names></name>
<name><surname>Ponzer</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Prolonged thromboprophylaxis with Dalteparin after surgical treatment of Achilles tendon rupture: a randomized, placebo-controlled study</article-title>. <source>J Orthop Trauma</source>. <year>2007</year>;<volume>21</volume>:<fpage>52</fpage>-<lpage>57</lpage>.</citation>
</ref>
<ref id="bibr29-1938640012463057">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pelet</surname><given-names>S</given-names></name>
<name><surname>Roger</surname><given-names>ME</given-names></name>
<name><surname>Belzile</surname><given-names>EL</given-names></name><etal/>
</person-group>. <article-title>The incidence of thromboembolic events in surgically treated ankle fracture</article-title>. <source>J Bone Joint Surg</source>. <year>2012</year>;<volume>94-A</volume>:<fpage>502</fpage>-<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr30-1938640012463057">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Falck-Ytter</surname><given-names>Y</given-names></name>
<name><surname>Francis</surname><given-names>CW</given-names></name>
<name><surname>Johanson</surname><given-names>NA</given-names></name><etal/>
</person-group>. <article-title>Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title>. <source>Chest</source>. <year>2012</year>;<volume>141</volume>(<supplement>2 suppl</supplement>):<fpage>e278S</fpage>-<lpage>e325S</lpage>.</citation>
</ref>
<ref id="bibr31-1938640012463057">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turpie</surname><given-names>AG</given-names></name>
<name><surname>Bauer</surname><given-names>KA</given-names></name>
<name><surname>Eriksson</surname><given-names>BI</given-names></name><etal/>
</person-group>. <article-title>Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip replacement surgery: a randomised double-blind trial</article-title>. <source>Lancet</source>. <year>2002</year>;<volume>359</volume>:<fpage>1721</fpage>-<lpage>1726</lpage>.</citation>
</ref>
<ref id="bibr32-1938640012463057">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lotke</surname><given-names>PA</given-names></name>
<name><surname>Lonner</surname><given-names>JH</given-names></name>
</person-group>. <article-title>The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty</article-title>. <source>Clin Orthop Relat Res</source>. <year>2006</year>;<volume>452</volume>:<fpage>175</fpage>-<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr33-1938640012463057">
<label>33.</label>
<citation citation-type="journal">
<collab>Pulmonary Embolism Prevention (PEP) Trial Collaborative Group</collab>. <article-title>Prevention of pulmonary embolism and deep vein thrombosis with low-dose aspirin</article-title>. <source>Lancet</source>. <year>2000</year>;<volume>355</volume>:<fpage>1295</fpage>-<lpage>1302</lpage>.</citation>
</ref>
<ref id="bibr34-1938640012463057">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leonardi</surname><given-names>MJ</given-names></name>
<name><surname>McGory</surname><given-names>ML</given-names></name>
<name><surname>Ko</surname><given-names>CY</given-names></name>
</person-group>. <article-title>The rate of bleeding complications after pharmacologic deep venous thrombosis prophylaxis: a systematic review of 33 randomized controlled trials</article-title>. <source>Arch Surg</source>. <year>2006</year>;<volume>141</volume>:<fpage>790</fpage>-<lpage>799</lpage>.</citation>
</ref>
<ref id="bibr35-1938640012463057">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amstutz</surname><given-names>HC</given-names></name>
<name><surname>Friscia</surname><given-names>DA</given-names></name>
<name><surname>Dorey</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement</article-title>. <source>J Bone Joint Surg</source>. <year>1989</year>;<volume>71-A</volume>:<fpage>321</fpage>-<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr36-1938640012463057">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lotke</surname><given-names>PA</given-names></name>
<name><surname>Callaghan</surname><given-names>JJ</given-names></name>
<name><surname>Dorr</surname><given-names>LD</given-names></name><etal/>
</person-group>. <article-title>Prophylaxis for thromboembolic disease</article-title>. <source>J Arthroplasty</source>. <year>2005</year>;<volume>20</volume>:<fpage>273</fpage>-<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr37-1938640012463057">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paiement</surname><given-names>GD</given-names></name>
<name><surname>Wessinger</surname><given-names>SJ</given-names></name>
<name><surname>Hughes</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Routine use of adjusted low dose warfarin to prevent venous thromboembolism after total hip replacement</article-title>. <source>J Bone Joint Surg</source>. <year>1993</year>;<volume>75-A</volume>:<fpage>893</fpage>-<lpage>898</lpage>.</citation>
</ref>
<ref id="bibr38-1938640012463057">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DiGiovanni</surname><given-names>CW</given-names></name>
</person-group>. <article-title>Current concepts review: heparin-induced thrombocytopenia</article-title>. <source>Foot Ankle Int</source>. <year>2008</year>;<volume>29</volume>:<fpage>1158</fpage>-<lpage>1167</lpage>.</citation>
</ref>
<ref id="bibr39-1938640012463057">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Girolami</surname><given-names>B</given-names></name>
<name><surname>Girolami</surname><given-names>A</given-names></name>
</person-group>. <article-title>Heparin-induced thrombocytopenia: a review</article-title>. <source>Semin Thromb Hemost</source>. <year>2006</year>;<volume>32</volume>:<fpage>803</fpage>-<lpage>809</lpage>.</citation>
</ref>
</ref-list></back>
</article>